Marina Konopleva, MD, PhD

No bio available.

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    ImmunoGen
    Topic:
    Research
    Date added:
    04/22/2024
    Date updated:
    04/22/2024
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Janssen
    Topic:
    Consulting
    Date added:
    04/22/2024
    Date updated:
    04/22/2024
  • Attribution:
    Self
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    Janssen
    Topic:
    Clinical Trials
    Date added:
    04/22/2024
    Date updated:
    04/22/2024
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Legend Biotech
    Topic:
    Consulting
    Date added:
    04/22/2024
    Date updated:
    04/22/2024
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    MEI Pharma
    Topic:
    Consulting
    Date added:
    04/22/2024
    Date updated:
    04/22/2024
  • Attribution:
    Self
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    MEI Pharma
    Topic:
    Research
    Date added:
    04/22/2024
    Date updated:
    04/22/2024
  • Attribution:
    Self
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    Pfizer
    Topic:
    Clinical Trials
    Date added:
    04/22/2024
    Date updated:
    04/22/2024
  • Attribution:
    Self
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    Precision Biosciences
    Topic:
    Research
    Date added:
    04/22/2024
    Date updated:
    04/22/2024
  • Attribution:
    Self
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    Rafael Pharmaceutical
    Topic:
    Research
    Date added:
    04/22/2024
    Date updated:
    04/22/2024
  • Attribution:
    Self
    Type of financial relationship:
    Intellectual Property Other
    Ineligible company:
    Reata Pharmaceutical
    Date added:
    04/22/2024
    Date updated:
    04/22/2024

Pages

Return to 2024 Summit on Hematological Cancers